TACE plus apatinib and camrelizumab versus TACE plus apatinib for CNLC Stage Ⅲ hepatocellular carcinoma:comparison of the clinical efficacy and safety
10.3969/j.issn.1008-794X.2025.07.013
- VernacularTitle:TACE联合双艾对比TACE联合阿帕替尼治疗CNLC Ⅲ期肝细胞癌的有效性及安全性
- Author:
Jie GU
1
;
Lei MA
;
Zhengyu ZHANG
;
Xinglong ZHU
;
Gaofeng XU
;
Chunhua DU
Author Information
1. 224006 江苏盐城 南京大学医学院附属盐城第一医院介入放射科
- Keywords:
hepatocellular carcinoma;
transcatheter hepatic artery chemoembolization;
apatinib;
programmed cell death-1 inhibitor;
prognostic factor analysis
- From:
Journal of Interventional Radiology
2025;34(7):756-761
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical efficacy and safety of transarterial chemoembolization(TACE)plus apatinib(Apa)and camrelizumab(Cam)and TACE plus Apa in treating CNLC stage Ⅲ hepatocellular carcinoma(HCC).Methods A total of 54 patients in Affiliated Yancheng No.1 People's Hospital,School of Medicine,Nanjing University with CNLC stage Ⅲ HCC were enrolled in this study.The patients were divided into triple treatment group(n=25,receiving TACE plus Apa and Cam)and dual treatment group(n=29,receiving TACE plus Apa).The overall survival(OS)and progression-free survival(PFS)were compared between the two groups.Univariate analysis and multivariate analysis were used to determine the independent influencing factors for OS and PFS.The target immunotherapy-related adverse reactions(TRAE)were analyzed.Results The median OS and PFS in the triple treatment group were 23.2 months and 10.9 months respectively,which were higher than 15.2 months and 5.8 months respectively in the dual treatment group(both P＜0.001).Multivariate analysis indicated that the therapeutic regimen and the type of portal vein tumor thrombosis(PVTT)were the independent factors affecting OS,while only the therapeutic regimen was the independent factor affecting PFS.The incidence of≥grade Ⅲ TRAE in the triple treatment group and the dual treatment group was 20％(5/25)and 17.2％(5/29)respectively,the difference between the two groups was not statistically significant(P＞0.05).Conclusion For the treatment of patients with CNLC stage Ⅲ HCC,TACE plus Apa and Cam is superior to TACE plus Apa in OS and PFS,and the type of PVTT and the therapeutic regimen are the independent prognostic factors associated with patient's survival.
